Brand Name
Adzynma
Generic Name
Apadamtase
View Brand Information FDA approval date: November 09, 2023
Form: Kit
What is Adzynma (Apadamtase)?
ADZYNMA is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” indicated for prophylactic or on demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura [see Use in Specific Populations.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Special Drug Use Surveillance of ADZYNMA Intravenous 1500 (All-Case Investigation)
Summary: This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from recombin...